Immunoassays for des-Arg9-bradykinin

Splenocytes from a female, BALB/c mouse immunized with bradykinin conjugated to ovalbumin with toluene diisocyanate were fused with mouse myeloma cells, X63/Ag8.653, using polyethylene glycol. Seventy-nine hybridomas were identified by ELISA to be making kinin reactive antibodies. In preliminary spe...

Full description

Saved in:
Bibliographic Details
Published in:Journal of immunoassay (Monticello, N.Y.) Vol. 14; no. 4; p. 227
Main Authors: Odya, C E, Carlin, R J, Yapa, R D, Soltani-Tehrani, B
Format: Journal Article
Language:English
Published: United States 01-12-1993
Subjects:
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Splenocytes from a female, BALB/c mouse immunized with bradykinin conjugated to ovalbumin with toluene diisocyanate were fused with mouse myeloma cells, X63/Ag8.653, using polyethylene glycol. Seventy-nine hybridomas were identified by ELISA to be making kinin reactive antibodies. In preliminary specificity studies it was determined that all of these hybridomas were producing antibodies more reactive with des-Arg9-bradykinin than with bradykinin. ELISAs were developed with the five clones that displayed the highest affinities for des-Arg9-bradykinin. Radioimmunoassays were developed for 3 of these 5 clones as well as with 5 monoclonal antibodies previously described (Odya and Lee 1990). The most sensitive des-Arg9-bradykinin assay developed was a radioimmunoassay in which carboxypeptidase B-treated [Tyr5]-bradykinin was the labeled antigen, clone OLNBK-5 was the antibody, and dextran-coated charcoal was used to separate bound from free radioactivity. The concentration of des-Arg9-bradykinin that inhibited 50% of the radioactive peptide binding was 0.08 +/- 0.03 nM. The relative specificity of this assay (des-Arg9-bradykinin = 100%) was: 29% bradykinin and about 1% with each of the following: lysyl-bradykinin, methionyl-lysyl-bradykinin, des-Arg1-bradykinin and des-Phe8-Arg9-bradykinin.
ISSN:0197-1522
DOI:10.1080/15321819308019852